Thera-SAbDab

ZATUXIMAB

>   Structural Summary
TherapeuticZatuximab
TargetEGFR
Heavy ChainEVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS
Light ChainDIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedSymphogen, Merck
Conditions Approvedna
Conditions ActiveColorectal cancer, Glioma, Non-small cell lung cancer
Conditions DiscontinuedHead and neck cancer, Oesophageal cancer
NotesFutuximab and Zatuximab are the same mAb

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]